e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syndax Pharmaceuticals, Inc. - Common Stock
(NQ:
SNDX
)
13.08
+0.23 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syndax Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
November 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 12, 2024
Via
Benzinga
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
November 12, 2024
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.
Via
Benzinga
Syndax Pharmaceuticals's Earnings: A Preview
November 04, 2024
Via
Benzinga
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 24, 2024
Via
Benzinga
Syndax Pharmaceuticals: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Earnings Preview: Syndax Pharmaceuticals
February 26, 2024
Via
Benzinga
Earnings Outlook For Syndax Pharmaceuticals
November 01, 2023
Via
Benzinga
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...
Via
Benzinga
Exposures
Product Safety
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
August 14, 2024
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Analyst Ratings for Syndax Pharmaceuticals
October 17, 2023
Via
Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
July 30, 2024
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
Via
InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 10, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 29, 2024
Via
Benzinga
SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024
May 08, 2024
SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
February 21, 2024
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.
Via
Talk Markets
What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
December 11, 2023
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with...
Via
Benzinga
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
December 10, 2023
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
November 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
October 11, 2023
Via
Benzinga
What's Going On With Syndax Pharmaceuticals Stock Monday?
October 02, 2023
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute...
Via
Benzinga
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 05, 2023
On Thursday, 369 companies hit new 52-week lows.
Via
Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
October 02, 2023
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
September 29, 2023
Via
Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
wpDiscuz
Insert
